Because administration of systemic IL-2 and neutralization of TGF-β or Treg depletion through anti-CD25 was shown to augment tumor survival in a CD8 T cell and/or NK cell dependent manner [13,27,42], the use of this immunotherapeutic regimen may also result in similar effects following HSCT. The gene discussed is TGFB1; the disease is neoplasm.